A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Roche
- 04 Oct 2017 Status changed from active, no longer recruiting to completed.
- 30 Sep 2017 This trial has been completed in Germany (end date: 2017-06-15).
- 23 Jun 2017 This trial has been completed in Spain (end date: 2017-06-15).